Literature DB >> 29653100

Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet.

Mohamed El-Sherbiny1, Mohamed Eldosoky2, Mohamed El-Shafey3, Gamal Othman4, Hany A Elkattawy5, Tamer Bedir6, Nehal Mohsen Elsherbiny7.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with hyperlipidemia, obesity and type II diabetes. Due to increasing prevalence of these diseases globally, NAFLD is considered as a common form of chronic liver diseases. Vitamin D is a fat soluble vitamin with reported anti-inflammatory, anti-oxidant and immune modulating activity. Hypovitaminosis D often coexists with NAFLD and various studies reported beneficial role of vitamin D in modulating NAFLD. However, variable oral bioavailability, poor water solubility, and chemical degradation hinder the clinical application of vitamin D.
PURPOSE: We evaluated the potential protective effect of Vitamin D nanoemulsion (developed by sonication and pH-Shifting of pea protein isolate and canola oil) compared to conventional vitamin D against liver injury in rats fed with high fat diet (HFD).
METHODS: We analyzed liver function enzymes, lipid profile, lipid metabolism, levels and histopathology of inflammation and fibrosis in rat liver tissues.
RESULTS: HFD fed rats exhibited deterioration of liver function, poor lipid profile, decreased fatty acid oxidation and up-regulation of inflammatory cytokines and extracellular matrix deposition. Vitamin D administration reduced elevated liver enzymes, improved lipid profile, enhanced fatty acid oxidation and attenuated liver inflammation and fibrosis. Interestingly, vitamin D nanoemulsion was superior to conventional vitamin D with remarkable hepatoprotective effect against HFD-induced liver injury.
CONCLUSION: This study demonstrated vitamin D nanoemulsion as a more efficient formulation with more prominent hepatoprotective effect against HFD-induced liver injury compared to conventional oral vitamin D.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29653100     DOI: 10.1016/j.cbi.2018.04.010

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

Review 1.  Bioavailability of nanoemulsion formulations vs conventional fat soluble preparations of cholecalciferol (D3) - An overview.

Authors:  Raman Kumar Marwaha; Aashima Dabas
Journal:  J Clin Orthop Trauma       Date:  2019-07-31

2.  Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice.

Authors:  Hyewon Lim; Heaji Lee; Yunsook Lim
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-04

3.  Protective effect of nano vitamin D against fatty degeneration in submandibular and sublingual salivary glands: A histological and ultrastructural study.

Authors:  Rasha Hamed Al-Serwi; Mohamed El-Sherbiny; Mohamed Ahmed Eladl; Ashwag Aloyouny; Ishrat Rahman
Journal:  Heliyon       Date:  2021-04-29

4.  Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol.

Authors:  Aisha Rafique; Anders Etzerodt; Jonas H Graversen; Søren K Moestrup; Frederik Dagnæs-Hansen; Holger Jon Møller
Journal:  Int J Nanomedicine       Date:  2019-04-23

5.  Self-microemulsifying oral fast dissolving films of vitamin D3 for infants: Preparation and characterization.

Authors:  Min Zhang; Tingrui Zhang; Ying Zou; Ping Han; Kehai Liu
Journal:  Food Sci Nutr       Date:  2019-07-11       Impact factor: 2.863

6.  Bioavailability by design - Vitamin D3 liposomal delivery vehicles.

Authors:  Paulina Dałek; Dominik Drabik; Halina Wołczańska; Aleksander Foryś; Małgorzata Jagas; Natalia Jędruchniewicz; Magdalena Przybyło; Wojciech Witkiewicz; Marek Langner
Journal:  Nanomedicine       Date:  2022-03-26       Impact factor: 6.096

Review 7.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.